(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 May 2011 (26.05.2011)

PCT

(10) International Publication Number
WO 2011/062930 A1

(51) International Patent Classification:
A61K 31/397 (2006.01)

(21) International Application Number:
PCT/US2010/056931

(22) International Filing Date:
17 November 2010 (17.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/261,813 17 November 2009 (17.11.2009) US

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE LLC** [US/US]; One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19102 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GILMER, Tona** [US/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US). **KUMAR, Rakesh** [US/US]; 1250 South Collegeville Road, Collegeville, PA 19426 (US). **LAQUERRE, Sylvie** [US/US]; 709 Swedeland Road, King Of Prussia, PA 19406 (US).

(74) Agents: **DERMOTT, Jonathan, M.** et al.; Glaxosmithkline, Corporate Intellectual Property, Uw2220, 709 Swedeland Road, P.o. Box 1539, King Of Prussia, PA 19406-0939 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,

[Continued on next page]

(54) Title: COMBINATION

Figure 1



(57) Abstract: A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1 - yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with

[Continued on next page]

WO 2011/062930 A1

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

a mTOR inhibitor, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or mTOR is beneficial, e.g. cancer.